162 related articles for article (PubMed ID: 29369970)
1. mTOR Inhibition Role in Cellular Mechanisms.
Zaza G; Granata S; Caletti C; Signorini L; Stallone G; Lupo A
Transplantation; 2018 Feb; 102(2S Suppl 1):S3-S16. PubMed ID: 29369970
[TBL] [Abstract][Full Text] [Related]
2. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects.
Granata S; Dalla Gassa A; Carraro A; Brunelli M; Stallone G; Lupo A; Zaza G
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187382
[TBL] [Abstract][Full Text] [Related]
4. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
Tedesco Silva H
Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
[No Abstract] [Full Text] [Related]
5. Cellular and molecular effects of the mTOR inhibitor everolimus.
Saran U; Foti M; Dufour JF
Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
[TBL] [Abstract][Full Text] [Related]
6. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
9. The pharmacology of mTOR inhibition.
Guertin DA; Sabatini DM
Sci Signal; 2009 Apr; 2(67):pe24. PubMed ID: 19383975
[TBL] [Abstract][Full Text] [Related]
10. Protection by mTOR Inhibition on Zymosan-Induced Systemic Inflammatory Response and Oxidative/Nitrosative Stress: Contribution of mTOR/MEK1/ERK1/2/IKKβ/IκB-α/NF-κB Signalling Pathway.
Sahan-Firat S; Temiz-Resitoglu M; Guden DS; Kucukkavruk SP; Tunctan B; Sari AN; Kocak Z; Malik KU
Inflammation; 2018 Feb; 41(1):276-298. PubMed ID: 29110153
[TBL] [Abstract][Full Text] [Related]
11. mTOR (Mechanistic Target of Rapamycin) Inhibition Decreases Mechanosignaling, Collagen Accumulation, and Stiffening of the Thoracic Aorta in Elastin-Deficient Mice.
Jiao Y; Li G; Li Q; Ali R; Qin L; Li W; Qyang Y; Greif DM; Geirsson A; Humphrey JD; Tellides G
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1657-1666. PubMed ID: 28751568
[TBL] [Abstract][Full Text] [Related]
12. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice.
Bridle KR; Sobbe AL; de Guzman CE; Santrampurwala N; Jaskowski LA; Clouston AD; Campbell CM; Nathan Subramaniam V; Crawford DH
Liver Int; 2015 Apr; 35(4):1451-63. PubMed ID: 24517519
[TBL] [Abstract][Full Text] [Related]
13. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
14. Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis.
Huo Y; Iadevaia V; Proud CG
Biochem Soc Trans; 2011 Apr; 39(2):446-50. PubMed ID: 21428917
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation.
Zhao Y; Zhao MM; Cai Y; Zheng MF; Sun WL; Zhang SY; Kong W; Gu J; Wang X; Xu MJ
Kidney Int; 2015 Oct; 88(4):711-21. PubMed ID: 26061549
[TBL] [Abstract][Full Text] [Related]
16. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
17. The evolution of the TOR pathway and its role in cancer.
Beauchamp EM; Platanias LC
Oncogene; 2013 Aug; 32(34):3923-32. PubMed ID: 23246968
[TBL] [Abstract][Full Text] [Related]
18. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
20. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
